Literature DB >> 24841948

Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells.

Yimin Lu1, Yuanhua Liu2, Jianzhong Jiang3, Zhaoqing Xi1, Ning Zhong4, Shunbin Shi5, Jinzhi Wang6, Xiaodong Wei7.   

Abstract

A hallmark of small cell lung cancer (SCLC) is frequent relapse characterized by newfound resistance to formerly efficacious chemotherapies. The prognosis for SCLC patients is particularly unfavorable. Aurora kinase A (AURKA), a member of the serine/threonine kinase family, is overexpressed across many types of human tumors. Recent studies have identified AURKA as an important factor in tumorigenesis, but little is known regarding its specific roles in SCLC. The aim of the present study was to establish the roles of AURKA in the molecular pathogenesis of human SCLC. In the present study, we constructed a lentiviral vector to express siRNA against AURKA (LV-AURKA siRNA). As we expected, the viral construct effectively suppressed the expression of the AURKA gene and protein in H446 and H1688 cell lines. Additionally, RNA interference of AURKA inhibited the colony formation and subsequent growth of H446 and H1688 cell lines by increasing the incidence of cell cycle arrest in the G2/M phase. Furthermore, suppression of AURKA by LV-AURKA siRNA also increased apoptosis of SCLC cells. A potential mechanism for the increase of apoptosis is the downregulation of Bcl-2 and upregulation of Bax. AURKA gene suppression may provide a novel, effective therapy for SCLC patients by inhibiting cell division and increasing the rate of apoptosis of SCLC cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24841948     DOI: 10.3892/or.2014.3194

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

Review 1.  Unravelling the biology of SCLC: implications for therapy.

Authors:  Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2017-05-23       Impact factor: 66.675

Review 2.  In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer.

Authors:  Noemí Reguart; Elba Marin; Jordi Remon; Roxana Reyes; Cristina Teixido
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

Review 3.  Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

Authors:  Triparna Sen; Carl M Gay; Lauren Averett Byers
Journal:  Transl Lung Cancer Res       Date:  2018-02

Review 4.  Signal pathways and precision therapy of small-cell lung cancer.

Authors:  Min Yuan; Yu Zhao; Hendrik-Tobias Arkenau; Tongnei Lao; Li Chu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2022-06-15

Review 5.  Relevance of genetic alterations in squamous and small cell lung cancer.

Authors:  Joshua K Sabari; Paul K Paik
Journal:  Ann Transl Med       Date:  2017-09

6.  Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.

Authors:  Yangchun Xie; Shan Zhu; Meizuo Zhong; Manhua Yang; Xiaofan Sun; Jinbao Liu; Guido Kroemer; Michael Lotze; Herbert J Zeh; Rui Kang; Daolin Tang
Journal:  Gastroenterology       Date:  2017-07-29       Impact factor: 22.682

Review 7.  New and emerging developments in extensive-stage small cell lung cancer therapeutics.

Authors:  Mamta Parikh; Jonathan Riess; Primo N Lara
Journal:  Curr Opin Oncol       Date:  2016-03       Impact factor: 3.645

8.  Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.

Authors:  Yong-Hui Ding; Zhi-Wei Zhou; Chun-Fang Ha; Xue-Yu Zhang; Shu-Ting Pan; Zhi-Xu He; Jeffrey L Edelman; Dong Wang; Yin-Xue Yang; Xueji Zhang; Wei Duan; Tianxin Yang; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-01-09       Impact factor: 4.162

9.  Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway.

Authors:  Kai Zhang; Jing Chen; Dongqin Chen; Jiayuan Huang; Bing Feng; Siqi Han; Yitian Chen; Haizhu Song; Wei De; Ziman Zhu; Rui Wang; Longbang Chen
Journal:  Oncotarget       Date:  2014-12-30

10.  Inhibition of Aurora-B suppresses HepG2 cell invasion and migration via the PI3K/Akt/NF-κB signaling pathway in vitro.

Authors:  Ren Feng Shan; Yun Fei Zhou; Ai Fen Peng; Zhi Gang Jie
Journal:  Exp Ther Med       Date:  2014-07-14       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.